• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受根治性膀胱切除术治疗的尿路上皮膀胱癌患者的预后评估:一种纳入组织学变体的新型简化模型

Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants.

作者信息

Ku Ja Hyeon, Yuk Hyeong Dong, Godoy Guiherme, Amiel Gilard E, Lerner Seth P

机构信息

Department of Urology, Seoul National University College of Medicine, Seoul, Korea.

Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.

出版信息

Bladder Cancer. 2018 Apr 26;4(2):195-203. doi: 10.3233/BLC-170156.

DOI:10.3233/BLC-170156
PMID:29732390
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5929296/
Abstract

PURPOSE

The aim of this study was to evaluate the clinical significance of histological variants (HV) and to develop a new and simple prediction model incorporating variant forms in patients who underwent radical cystectomy for urothelial carcinoma (UC).

MATERIALS AND METHODS

We analyzed the data of 365 patients. We evaluated whether HV were independent predictors of survival. A new scoring model was developed using the regression coefficients from the multivariate Cox proportional hazard model. The patients were divided into three groups on the basis of the score: low-, intermediate- and high-risk. To evaluate the performance of the model, we assessed models in terms of discrimination and calibration.

RESULTS

Patients(median age; 68.5 years) with pure form and squamous differentiation did not differ significantly but statistical analysis of the survival curves of patients with pure form and other variants revealed a statistically significant difference in terms of cancer-specific survival (CSS) ( = 0.005) and overall survival (OS) ( = 0.010). According to the new scoring model HV, the 5-yr CSS rate in each group was 93.3%, 82.9% and 50.5%, respectively. The 5-yr OS rate in each group was 90.0%, 66.3% and 33.2%, respectively. Model discrimination was good for all year models. Calibration was also adequate for the model in all year models.

CONCLUSIONS

HV were found to be important independent prognostic factors in urothelial bladder cancer. This paper presents a new prognostic model incorporating variant forms for predicting CSS and OS in these patients.

摘要

目的

本研究旨在评估组织学变体(HV)的临床意义,并开发一种新的、简单的预测模型,该模型纳入接受根治性膀胱切除术的尿路上皮癌(UC)患者的变体形式。

材料与方法

我们分析了365例患者的数据。我们评估了HV是否为生存的独立预测因素。使用多变量Cox比例风险模型的回归系数开发了一种新的评分模型。根据评分将患者分为三组:低风险、中风险和高风险。为了评估模型的性能,我们从区分度和校准方面评估了模型。

结果

纯形式和鳞状分化的患者(中位年龄;68.5岁)无显著差异,但对纯形式和其他变体患者的生存曲线进行统计分析显示,在癌症特异性生存(CSS)(=0.005)和总生存(OS)(=0.010)方面存在统计学显著差异。根据新的评分模型HV,每组的5年CSS率分别为93.3%、82.9%和50.5%。每组的5年OS率分别为90.0%、66.3%和33.2%。所有年份模型的模型区分度都很好。所有年份模型的模型校准也足够。

结论

发现HV是尿路上皮膀胱癌重要的独立预后因素。本文提出了一种新的预后模型,该模型纳入变体形式以预测这些患者的CSS和OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7d/5929296/123de83ebe03/blc-4-blc170156-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7d/5929296/e06f7f664e2c/blc-4-blc170156-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7d/5929296/123de83ebe03/blc-4-blc170156-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7d/5929296/e06f7f664e2c/blc-4-blc170156-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7d/5929296/123de83ebe03/blc-4-blc170156-g002.jpg

相似文献

1
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants.接受根治性膀胱切除术治疗的尿路上皮膀胱癌患者的预后评估:一种纳入组织学变体的新型简化模型
Bladder Cancer. 2018 Apr 26;4(2):195-203. doi: 10.3233/BLC-170156.
2
Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants.根治性膀胱切除术治疗单纯尿路上皮膀胱癌及组织学变异型时同时存在原位癌的肿瘤学结局。
Urol Oncol. 2022 Feb;40(2):61.e9-61.e19. doi: 10.1016/j.urolonc.2021.07.009. Epub 2021 Jul 29.
3
Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.膀胱尿路上皮癌伴鳞状或腺性分化患者新辅助化疗及根治性膀胱切除术后的临床结局
Clin Genitourin Cancer. 2016 Feb;14(1):82-8. doi: 10.1016/j.clgc.2015.08.006. Epub 2015 Aug 29.
4
The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.浆细胞样变异型组织学对根治性膀胱切除术后膀胱癌患者生存的影响。
Eur Urol Focus. 2019 Jan;5(1):104-108. doi: 10.1016/j.euf.2017.06.013. Epub 2017 Jun 27.
5
The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.根治性膀胱切除术治疗的膀胱尿路上皮癌患者中组织学亚型对肿瘤学结局的影响。
Anticancer Res. 2020 Aug;40(8):4787-4793. doi: 10.21873/anticanres.14481.
6
Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.卡诺夫斯基体能状态可预测尿路上皮癌根治性膀胱切除术后的总生存期、癌症特异性生存期和无进展生存期。
World J Urol. 2014 Apr;32(2):385-91. doi: 10.1007/s00345-013-1110-7. Epub 2013 Jun 12.
7
The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.鳞状和腺体分化对膀胱癌根治性膀胱切除术后生存的影响。
J Urol. 2012 Aug;188(2):405-9. doi: 10.1016/j.juro.2012.04.020. Epub 2012 Jun 14.
8
Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.膀胱尿路上皮癌中鳞状分化的临床意义
Cancer Control. 2018 Jan-Dec;25(1):1073274818800269. doi: 10.1177/1073274818800269.
9
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?病理复查过程中组织学分型再分类的影响——膀胱癌中的威尔·罗杰斯效应证据?
J Urol. 2013 Nov;190(5):1692-6. doi: 10.1016/j.juro.2013.05.040. Epub 2013 May 23.
10
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?辅助化疗对根治性膀胱切除术治疗肌层浸润性膀胱癌伴不良特征和变异组织学患者的影响:组织学亚型重要吗?
Cancer. 2019 May 1;125(9):1449-1458. doi: 10.1002/cncr.31952. Epub 2019 Jan 8.

引用本文的文献

1
Current status of the focused series "Urothelial Carcinoma".聚焦系列“尿路上皮癌”的现状
Transl Cancer Res. 2020 Oct;9(10):6534-6536. doi: 10.21037/tcr-2020-uc-10.
2
Computed-tomography based scoring system predicts outcome for clinical lymph node-positive patients undergoing radical cystectomy.基于计算机断层扫描的评分系统预测行根治性膀胱切除术的临床淋巴结阳性患者的结局。
Int Braz J Urol. 2022 Jan-Feb;48(1):89-98. doi: 10.1590/S1677-5538.IBJU.2021.0329.
3
Effect of bladder cancer variant histology on survival outcome in patients treated with radical cystectomy: A single-centre experience.

本文引用的文献

1
Characteristics and clinical significance of histological variants of bladder cancer.膀胱癌的组织学变异特征及临床意义。
Nat Rev Urol. 2017 Nov;14(11):651-668. doi: 10.1038/nrurol.2017.125. Epub 2017 Sep 12.
2
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
3
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
膀胱癌变异组织学对接受根治性膀胱切除术患者生存结局的影响:单中心经验
Urol Ann. 2021 Jul-Sep;13(3):288-295. doi: 10.4103/UA.UA_95_20. Epub 2021 Jul 14.
4
The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis.鳞状分化在膀胱尿路上皮癌患者中的临床病理特征及预后价值:一项荟萃分析。
World J Urol. 2020 Feb;38(2):323-333. doi: 10.1007/s00345-019-02771-1. Epub 2019 Apr 22.
验证用于预测膀胱癌患者全因死亡率、癌症特异性死亡率和复发的术后列线图。
Eur Urol. 2012 Jan;61(1):58-64. doi: 10.1016/j.eururo.2011.07.066. Epub 2011 Aug 9.
4
The revised ACPGBI model is a simple and accurate predictor of operative mortality after potentially curative resection of colorectal cancer.经修订的 ACPGBI 模型是预测结直肠癌潜在可治愈性切除术后手术死亡率的一种简单而准确的方法。
Ann Surg Oncol. 2011 Dec;18(13):3680-5. doi: 10.1245/s10434-011-1805-1. Epub 2011 Jun 15.
5
Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.基于术前血清 C 反应蛋白和标准病理危险因素的膀胱癌新预后预测模型的建立:TNR-C 评分。
BJU Int. 2011 Dec;108(11):1800-5. doi: 10.1111/j.1464-410X.2011.10234.x. Epub 2011 Apr 20.
6
How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.我还有多长时间?对转移性乳腺癌一线化疗初治患者的典型、最佳和最差情况进行估算:近期随机试验的系统评价。
J Clin Oncol. 2011 Feb 1;29(4):456-63. doi: 10.1200/JCO.2010.30.2174. Epub 2010 Dec 28.
7
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases.膀胱微乳头状尿路上皮癌:72 例临床病理分析。
Pathology. 2010 Dec;42(7):650-4. doi: 10.3109/00313025.2010.522173.
8
Predicting individual outcomes after radical cystectomy: an external validation of current nomograms.预测根治性膀胱切除术(radical cystectomy)后的个体预后:当前列线图(nomograms)的外部验证。
BJU Int. 2010 Aug;106(3):342-8. doi: 10.1111/j.1464-410X.2009.09138.x. Epub 2009 Dec 11.
9
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.多种分子标志物联合可提高局部晚期和淋巴结阳性膀胱癌患者的预后。
J Urol. 2010 Jan;183(1):68-75. doi: 10.1016/j.juro.2009.08.115.
10
Prognosis and prognostic research: application and impact of prognostic models in clinical practice.预后与预后研究:预后模型在临床实践中的应用与影响
BMJ. 2009 Jun 4;338:b606. doi: 10.1136/bmj.b606.